

1. Leopold JA. Initial Triple Pharmacotherapy in Pulmonary Arterial Hypertension: Is More Necessarily Better? *J Am Coll Cardiol*. 2021 Oct 5;78(14):1404-1406. doi: 10.1016/j.jacc.2021.08.007. PMID: 34593121; PMCID: PMC8637933.
2. Hirani N, Brunner NW, Kapasi A, Chandy G, Rudski L, Paterson I, Langleben D, Mehta S, Mielniczuk L; CCS/CTS Pulmonary Hypertension Committee. Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. *Can J Cardiol*. 2020 Jul;36(7):977-992. doi: 10.1016/j.cjca.2019.11.041. PMID: 32682511.
3. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29. PMID: 26320113.
4. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. *N Engl J Med*. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. PMID: 26308684.
5. Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, Bouvaist H, Dauphin C, Picard F, Bulfon S, Montani D, Humbert M, Simonneau G. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. *Eur Respir J*. 2014 Jun;43(6):1691-7. doi: 10.1183/09031936.00116313. Epub 2014 Mar 13. PMID: 24627535.
6. Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grünig E, Hoeper MM, Martin N, Mathai SC, McLaughlin VV, Perchenet L, Poch D, Saggarr R, Simonneau G, Galiè N. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. *J Am Coll Cardiol*. 2021 Oct 5;78(14):1393-1403. doi: 10.1016/j.jacc.2021.07.057. PMID: 34593120
7. Suzuki S, Asano R, Aoki T, *et al* Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension *Open Heart* 2022;9:e002054. doi: 10.1136/openhrt-2022-002054
8. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Five-Year outcomes of patients enrolled in the REVEAL Registry. *Chest*. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300. PMID: 26066077.
9. Deng J. Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Cardiothorac Surg*. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4. PMID: 34670595; PMCID: PMC8527803.

10. Sitbon O, Gomberg-Maitland M, Granton J, Lewis MJ, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. Clinical trial design and new therapies for pulmonary arterial hypertension. *Eur Respir J*. 2019 Jan 24;53(1):1801908. doi: 10.1183/13993003.01908-2018. PMID: 30545975; PMCID: PMC6351342.
11. Mohammadi A, Matos WF, Intriago C, Thakkar K, Jahan N, Shah H, Nishu RI, Marzban S. Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension. *Cureus*. 2021 Sep 22;13(9):e18191. doi: 10.7759/cureus.18191. PMID: 34707962; PMCID: PMC8533662.
12. Barnes H, Yeoh HL, Fothergill T, Burns A, Humbert M, Williams T. Prostacyclin for pulmonary arterial hypertension. *Cochrane Database Syst Rev*. 2019 May 1;5(5):CD012785. doi: 10.1002/14651858.CD012785.pub2. PMID: 31042010; PMCID: PMC6492481.
13. Suzuki S, Asano R, Aoki T, *et al* Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension *Open Heart* 2022;9:e002054. doi: 10.1136/openhrt-2022-002054
14. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL. Five-Year outcomes of patients enrolled in the REVEAL Registry. *Chest*. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300. PMID: 26066077.
15. Deng J. Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension. *J Cardiothorac Surg*. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4. PMID: 34670595; PMCID: PMC8527803.